VIADERMA, INC.
4640 Admiralty Way, Suite 500
Marina Del Rey, CA 90292
310-496-5744

VIADERMA, INC.
COMPANY INFORMATION AND DISCLOSURE STATEMENT

Part A: General Company Information

As used in this disclosure statement, the terms "we", "us", "our", “VDRM”, and the "Company" means, ViaDerma, Inc., a Nevada corporation.

Item I: The exact name of the issuer and its predecessor (if any).

Current since May 6, 2014:	ViaDerma, Inc.
Before May 6, 2014:	Décor Products International, Inc.
Before July, 2009:	Murals By Maurice, Inc.

Item II: The address of the issuer’s principal executive offices

ViaDerma, Inc.
4640 Admiralty Way, Suite 500
Marina Del Rey, CA 90292
Ph. 310-496-5744
E-mail: info@viadermalicensing.com
Website: http://www.viadermalicensing.com

Item III: The jurisdiction(s) and date of the issuer’s incorporation or organization.

ViaDerma, Inc. (the “Company”) was incorporated in the State of Florida, United States of America on January 11, 2007 in name of Murals By Maurice, Inc. On July 1, 2009, the Company changed its name to Décor International Products, Inc. On January 20, 2010 the Company filed Articles of Merger with the Secretary of State of Florida to effect a merger with Wide Broad Group, LTD a corporation incorporated in the British Virgin Islands. On May 13, 2010, Décor International Products, Inc. filed articles of merger and redomicile to the State of Nevada with DCRD Merger Sub, Inc. The resulting entity, newly domiciled in Nevada remained Décor Products International, Inc. until May 6, 2014 when it changed its name to ViaDerma, Inc.

Part B: Share Structure

Item IV: The exact title and class of securities outstanding.

Security Symbol:	VDRM
CUSIP Number:	92555K101
Classes:	Common Stock
Authorized:	750,000,000
Outstanding:	436,214,603
Security Symbol:	N/A
CUSIP Number:	N/A
Classes:	Convertible Preferred Stock
Authorized:	50,000,000
Outstanding:	31,000,000

Item V: Par or stated value and description of the security.

A. Par or Stated Value.

Common Stock: $ .0001 per share
Convertible Preferred Stock: $.001 per share

B. Common or Preferred Stock.

1. For common equity, describe any dividend, voting and preemption rights.

Each share of Common Stock is entitled to one vote, which shares do not have pre-emptive rights. Dividends, if any, are declared at the discretion of the Board of Directors.

From inception, the Company has never declared or paid any cash dividends on shares of its common stock and the Company does not anticipate declaring or paying any cash dividends in the foreseeable future. The decision to declare any future cash dividends will depend upon the Company's results of operations, financial condition, current and anticipated cash needs, contractual restrictions, restrictions imposed by applicable law and other factors that the Company's board of directors deem relevant. Although it is the Company's intention to utilize all available funds for the development of its business, no restrictions are in place that would limit its ability to pay dividends. The payment of any future cash dividends will be at the sole discretion of the Company's board of directors.

2. For preferred stock, describe the dividend, voting, conversion and liquidation rights as well as redemption or sinking fund provisions.

The Board of Directors of the Company shall have the authority, by resolution or resolutions, to divide the convertible preferred stock into series, to establish and fix the distinguishing designation of each such series and the number of shares thereof and, within the limitations of applicable law of the state of Nevada or as otherwise set forth in this article, to fix and determine the relative rights and preferences of the shares of each series so established from time to time, thereof. The initial voting rights, preferences and any qualifications, limitations, and other relative rights of the convertible preferred stock are set forth below:

(1) Authorization Number. The class of Preferred Stock consists of 50,000,000 shares, $.0001 par value. On August 16, 2016, the Company filed a Certificate of Amendment with the Secretary of State of Nevada to change the par value of common stock from $.001 per share to $.0001 per share. The par value of preferred stock remains unchanged. The Preferred Stock is authorized by the Board of Directors of this Corporation and shall be senior to the common stock.

(2) Conversion into Common Stock.

(a) Right to Convert. Each share of Preferred Stock shall be convertible, at the option of the holder thereof, at any time after the date of issuance (the "Conversion Date") into Ten (10) shares of fully paid and non-assessable shares of Common Stock of the Corporation (the "Conversion Ratio").

(b) Mechanics of Conversion. Before any holder shall be entitled to convert, he shall surrender the certificate or certificates representing Preferred Shares to be converted, duly endorsed or accompanied by proper instruments of transfer, at the office of the Corporation or of any transfer agent, and shall give written notice to the Corporation at such office that he elects to convert the same. The Corporation shall, as soon as practicable thereafter, issue a certificate or certificates for the number of shares of Common Stock to which the holder shall be entitled. The Corporation shall, as soon as practicable after delivery of such certificates, or such agreement and indemnification in the case of a lost, stolen or destroyed certificate, issue and deliver to such holder of Preferred Stock a certificate or certificates for the number of shares of Common Stock to which such holder is entitled as aforesaid and a check payable to the holder in the amount of any cash amounts payable as the result of a conversion into fractional shares of Common Stock. Such conversion shall be deemed to have been made immediately prior to the close of business on the date of such surrender of the shares of Preferred Stock to be converted.

(c) Adjustment to Conversion Ratio.

(1) Merger or Reorganization. In case of any consolidation or merger of the Corporation as a result of which holder of Common Stock become entitled to receive other stock or securities or property, or in case of any conveyance of all or substantially all of the assets of the Corporation to another corporation, the Corporation shall mail to each holder of Preferred Stock at least thirty (30) days prior to the consummation of such event a notice thereof, and each such holder shall have the option to either (i) convert such holder's shares of Preferred Stock into shares of Common Stock pursuant to this Section 2 and thereafter receive the number of shares of stock or other securities or property to which a holder of the number of shares of Common Stock of the Corporation deliverable upon conversion of such Preferred Stock would have been entitled upon such consolidation, merger or conveyance, or (ii) exercise such holder's rights pursuant to Section 3(a). Unless otherwise set forth by the Board of Directors, the Conversion Ratio shall not be affected by a stock dividend or subdivision (stock split) on the Common Stock of the Corporation, or a stock combination (reverse stock split) or stock consolidation by reclassification of the Common Stock. However, once the Preferred Stock has been converted to Common Stock, it shall be subject to all corporate actions that affect or modify the common stock.

(d) No Impairment. The Corporation will not, by amendment of its Articles of Incorporation, this Certificate of Designation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed hereunder by the Corporation, but will at all times in good faith assist in the carrying out of all the provisions of this Section 2 and in the taking of all such action as may be necessary or appropriate in order to protect the Conversion Rights of the holders of the Preferred Stock against impairment.

(e) Certificate as to Adjustments. Upon the occurrence of each adjustment or readjustment of the Conversion Ratio of the Preferred Stock pursuant to this Section 2, the Corporation at its expense shall promptly compute such adjustment or readjustment in accordance with the terms hereof and furnish to each holder of Preferred Stock a certificate setting forth such adjustment or readjustment and the calculation on which such adjustment or readjustment is based. The Corporation shall, upon the written request at any time of any holder of Preferred Stock, furnish or cause to be furnished to such holder a like certificate setting forth (i) such adjustment and readjustment, (ii) the Conversion Ratio for the Preferred Stock at the time in effect and (iii) the number of shares of Common Stock and the amount, if any, of other property which at the time would be received upon the conversion of the Preferred Stock.

(f) Notice of Record Date. In the event of any taking by the Corporation of a record of the holders of any class of securities for the purpose of determining the holders thereof who are entitled to receive any dividend (other than a cash dividend which is the same as cash dividends paid in previous quarter) or other distribution, the Corporation shall mail to each holder of Preferred Stock at least ten (10) days prior to the date specified herein, a notice specifying the date on which any such record is to be taken for the purpose of such dividend or distribution.

(g) Common Stock Reserve. The corporation shall reserve and keep available out of its authorized but unissued Common Stock such number of shares of Common Stock as shall from time to time be sufficient to effect conversion of the Preferred Stock.

(3) Liquidation Preference. (a) In the event of any liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary (a "Liquidation"), the assets of the Corporation available for distribution to its stockholders shall be distributed as follows:

(1) The holders of the Preferred Stock shall be entitled to receive, prior to the holders of Common Stock and prior and in preference to any distribution of the assets or surplus funds of the Corporation to the holders of any other shares of stock of the corporation by reason of their ownership of such stock, an amount equal to $1.00 per share with respect to each share of Preferred Stock.

(2) If upon occurrence of a Liquidation the assets and funds thus distributed among the holders of the Preferred Stock shall be insufficient to permit the payment to such holders of the full preferential amount, then the entire assets and funds of the Corporation legally available for distribution shall be distributed among the holders of the Preferred Stock ratably in proportion to the full amounts to which they would otherwise be respectively entitled.

(3) After payment of the full amounts to the holders of Preferred Stock as set forth above in paragraph (3)(a)(1), any remaining assets of the Corporation shall be distributed pro rata to the holders of the Preferred Stock and Common Stock (in the case of the Preferred Stock, on an "as converted" basis into Common Stock).

(b) For purposes of this Section 3, and unless a majority of the holders of the Preferred Stock affirmatively vote or agree by written consent to the contrary, a Liquidation shall be deemed to include (i) the acquisition of the Corporation by another entity by means of any transaction or series of related transactions (including, without limitation, any reorganization, merger or consolidation) and (ii) a sale of all or substantially all of the assets of the Corporation, unless the Corporation's stockholders of records as constituted immediately prior to such acquisition or sale will, immediately after such acquisition or sale (by virtue of securities issued as consideration for the Corporation's acquisition or sale or otherwise) hold at least fifty percent (50%) of the voting power of the surviving or acquiring entity.

(c) If any of the assets of the Corporation are to be distributed other than in cash under this Section 3, then the board of directors of the Corporation shall promptly engage independent competent appraisers to determine the value of the assets to be distributed to the holders of Preferred Stock or Common Stock. The Corporation shall, upon receipt of such appraiser's valuation, give written notice to each holder of shares of Preferred Stock or Common Stock of the appraiser's valuation.

(4) Voting Rights. Except as otherwise required by law, the holders of Preferred Stock and the holders of Common Stock shall be entitled to notice of any stockholders' meeting and to vote as a single class upon any matter submitted to the stockholders for a vote as follows: (i) the holders of Preferred Stock shall have one vote for each full share of Common Stock into which a share of Preferred Stock would be convertible at the ratio of 1:10 on the record date for the vote, or, if no such record date is established, at the date such vote is taken or any written consent of stockholders is solicited; and (ii) the holders of Common Stock shall have one vote per share of Common Stock held as of such date.

(5) Limitation. No holder of shares of the Preferred Stock shall be allowed to vote and convert into any position that would result the Preferred Stock Holder to hold more than nine and nine tenths percent (9.9%) of the Corporation's outstanding shares of Common Stock.

(6) Covenants. In addition to any other rights provided by law, the Corporation shall not, without first obtaining the affirmative vote or written consent of the holders of a majority of the outstanding shares of Preferred Stock, do any of the following:

a. take any action which would either alter, change or affect the rights, preferences, privileges or restrictions of the Preferred Stock or increase the number of shares of such series authorized hereby or designate any other series of Preferred Stock;

b. increase the size of any equity incentive plan (s) or arrangements;

c. make fundamental changes to the business of the Corporation;

d. make any changes to the terms of the Preferred Stock or to the Corporation's Articles of Incorporation or Bylaws, including by designation of any stock;

e. create any new class of shares having preferences over or being on a parity with the Preferred Stock as to dividends or assets, unless the purpose of creation of such class is, and the proceeds to be derived from the sale and issuance thereof are to be used for, the retirement of all Preferred Stock then outstanding;

f. incur any indebtedness in excess of $1,000,000;

g. make any change in the size or number of authorized directors;

h. repurchase any of the Corporation's Common Stock;

i. sell, convey or otherwise dispose of, or create or incur any mortgage, lien, charge or encumbrance on or security interest in or pledge of, or sell and leaseback, all or substantially all of the property or business of the Corporation or more than 50% of the stock of the Corporation;

j. make any payment of dividends or other distributions or any redemption or repurchase of common stock or options or warrants to purchase common stock of the Corporation which would frustrate the right of the Preferred Stock to its cumulative dividend; or

k. make any sale of additional Preferred Stock.

(7) Reissuance. No share or shares of Preferred Stock acquired by the Corporation by reason of conversion, all such shares thereafter shall be returned to be the status of unissued shares of Preferred Stock of the Corporation.

(8) Directors. The holders of Preferred Stock and Common Stock voting together as a class shall be entitled to elect the directors comprising the Board of Directors (and to fill any vacancies with respect thereto).

3. Describe any other material rights of common or preferred stockholders.

None.

4. Describe any provision in issuer's charter or by-laws that would delay, defer or prevent a change in control of the issuer.

None.

Item VI: The number of shares or total amount of the securities outstanding for each class of securities authorized.

Common Stock

Period end date:	November 13, 2017
Number of Shares Outstanding:	436,214,603
Number of Shares Authorized:	750,000,000
Public Float:	322,396,271
Total Number of beneficial Shareholders [(1):]	2
Total Number of Shareholders of Record:	71

Period end date:	December 31, 2016
Number of Shares Outstanding:	262,319,103
Number of Shares Authorized:	400,000,000
Public Float:	143,942,325
Total Number of beneficial Shareholders [(1):]	3
Total Number of Shareholders of Record:	76

Period end date:	December 31, 2015
Number of Shares Outstanding:	111,042,787
Number of Shares Authorized:	150,000,000
Public Float:	37,061,509
Total Number of beneficial Shareholders [(1):]	5
Total Number of Shareholders of Record:	75

(1) Shareholders currently hold more than 5%

Convertible Preferred Stock

Period end date:	November 13, 2017
Number of Shares Outstanding:	31,000,000
Number of Shares Authorized:	50,000,000
Public Float:	N/A
Total Number of beneficial Shareholders [(2):]	1
Total Number of Shareholders of Record:	1

Period end date:	December 31, 2016
Number of Shares Outstanding:	1,000,000
Number of Shares Authorized:	50,000,000
Public Float:	N/A
Total Number of beneficial Shareholders:	1
Total Number of Shareholders of Record:	1

Period end date:	December 31, 2015
Number of Shares Outstanding:	1,000,000
Number of Shares Authorized:	50,000,000
Public Float:	N/A
Total Number of beneficial Shareholders:	1
Total Number of Shareholders of Record:	1

(2) Shareholder currently holds 96.77%

Part C: Business Information

Item VII: The name address of the transfer agent

ClearTrust, LLC
16540 Pointe Village Drive
Suite 206
Lutz, Florida 33558
(813) 235-4490

Note: ClearTrust, LLC is a registered transfer agent with the SEC.

Item VIII: The nature of the issuer's business

A. Business Development:

ViaDerma, Inc's lead product is an FDA registered topical antibiotic marketed under the brand names of Vitastem or Viabecline. The Company also has products in development in the following fields; anti-aging skin care, pain management, hair-loss, and toenail fungus. The products are based on a patent pending delivery system technology that allows for rapid mass transfer of the pharmaceutical active ingredient across the skin and into the body to provide immediate localized therapy.

The Company utilizes a specific Trade Secret Formulation System in the manufacture of all the products.

On January 31, 2014, the Company purchased an exclusive license (the "License") on the patent pending technology from Dr. Howard Phillips represented by US Patent application #20130190274. The Company amended the License on January 20, 2017 such that it is now a non-exclusive distribution and licensing agreement.

Apart from the technology licensed from Dr. Howard Phillips, the Company is currently using a second-generation transdermal technology to manufacture and develop its products. This technology was exclusively licensed from a related party. During 2016, provisional patents were been filed on this technology. The Company received provisional patent #62433964 'AQUEOUS TOPICAL SOLUTIONS for this technology. The Company believes the newer technology has additional benefits and plans to incorporate this topical delivery system into most, if not all, of its future products.

Vitastem and Viabecline are currently listed with the FDA. Detailed product information is available online by accessing the Government website, DailyMed.

In June 2017, the Company received notification that its newer product Prolayed (15ml), was also registered with the FDA.

1. The form of organization of the issuer:

Nevada C Corporation.

2. The year that the issuer (or any predecessor) was organized:

Incorporated in the State of Florida, United States of America on January 11, 2007 in the name of Murals By Maurice, Inc.

3. The issuer's fiscal year end date:

December 31

4. Whether the issuer (or any predecessor) has been in bankruptcy, receivership or any similar proceeding:

During 2014, the Company defaulted on a note payable to a creditor which resulted in a legal action to issue 520,000 common shares and 1,666,667 preferred shares to the creditor. During the year ended December 31, 2014, 666,667 shares of preferred stock of the Company were converted into 6,666,670 shares of common stock at the ratio of 10:1 upon the request from the preferred shareholder.

5. Any material reclassification, merger, consolidation, or purchase or sale of a significant amount of assets:

The Company was originally incorporated in the State of Florida, United States of America on January 11, 2007 in the name of Murals By Maurice, Inc. (MUBM)

In January 20, 2010 the Company entered into a merger agreement with Wide Broad Group, LTD. Décor Products International, Inc. acquired 100% of the issued and outstanding shares of Wide Broad Group, LTD. In exchange for a new issuance of 400,000 shares of common stock of MUBM, and a simultaneous retirement to the treasury 149,000 shares of common stock (the control shares) held in the name of Maurice Katz in a transaction intended to qualify as a share exchange pursuant to Section 350 and 368 of the internal Revenue Code of 1986 as amended.

On May 13, 2010, the Company entered into a second merger agreement with agreement with DCRD Merger Sub, Inc. for the purpose of reincorporation of the Florida Corporation in the State of Nevada. By merging with and into the Nevada Corporation and conducted a combination of its shares of common stock such that each three (3) shares of the Florida Corporation common stock for each of one (1) share of Nevada Corporation common stock to be effectuated upon the execution of the merger agreement.

On or about March 21, 2014, the Company acquired ViaDerma II, Inc. a Nevada corporation which holds the intellectual property purchased from Dr. Phillips as well as the daily operations run by our President. The Company subsequently changed its name to ViaDerma, Inc. to reflect the new direction of the Company as well as it current products. On June 4, 2014, 44,000,000 shares were issued to Dr. Chris Ayo Otiko in connection with this acquisition. The Company has since added additional intellectual property to its portfolio as described herein.

6. Any default of the terms of any note, loan, lease, or other indebtedness or financing arrangement requiring the issuer to make payments:

The Company is currently in default on a series of promissory notes with outstanding principal balance of $266,000 as of September 30, 2017. Those amounts continue to accrue interest. During the nine months ended September 30, 2017, the Company recorded the default interest and penalty of the Notes in amount of approximately $55,629, and the accrued interest payable of $323,631 related to the default notes. The Company is negotiating a payment and a partial settlement on those notes.

During 2017, certain note holders and its assigns converted a portion of principal in amount of $61,502, including $10,000 conversion cost reimbursement, and accrued interest of $40,391 into shares of common stock of the Company. Of this amount, 78,395,500 shares of common stock were issued during the first quarter of 2017, 35,000,000 shares of common stock were issued during the second quarter of 2017, 41,000,000 shares issued during the third quarter of 2017, and additional 15,000,000 shares of common stock were issued subsequent to September 30, 2017, towards settlements of these obligations.

7. Any change of control:

In April of 2010, Rui Sheng Liu, an individual resident of the Peoples Republic of China, was elected President of Décor Products International, Inc.

On April 20, 2010, the Board of Directors of the Company appointed Rui Sheng Liu as of the company.

Simultaneously on April 20, 2010, Maurice Katz, the Company's former President and Founder, resigned all his officer and director positions with the Company.

On March 31, 2014, the Board of Directors of the Company appointed Dr. Chris Ayo Otiko, as President, Sectary and Treasurer of the Company.

8. Any increase of 10% or more of the same class of outstanding equity securities:

As the result of a legal action for one of our defaulted promissory notes and the simultaneous issuance to Dr. Chris Ayo Otiko, our current President, the Company issued 44,520,000 shares of common stock which represented more than 10% of the outstanding common shares. Additionally, as part of the same action 1,666,667 shares of preferred stock were issued for the benefit of the creditor.

On June 5, 2014, a portion of principal in amount of $76,800 and accrued interest payable in amount of $48,000 were converted into 10,400,000 shares of common stock of the Company at the conversion price of $0.012 per share.

During the year ended December 31, 2015, a portion of principal in amount of $148,200 and accrued interest payable in amount of $148,969 were converted into 24,764,001 shares of common stock of the Company at the conversion price of $0.012 per share.

During the year ended December 31, 2016, the note holders and its assigns converted a portion of principal and accrued interest in amount of $6,532 and $47,843, respectively, plus conversion cost reimbursement of $6,000, into 120,750,000 shares of common stock of the Company at the conversion price of $0.0005 per share.

During the first quarter of 2017, the note holder and its assigns converted a portion of principal and accrued interest in amount of $24,268 and $7,472, respectively, plus conversion cost reimbursement of $5,000, into 73,482,000 shares of common stock of the Company at the conversion price of $0.0005 per share.

During the first quarter of 2017, 30,000,000 shares of preferred stock of the Company were issued to Dr. Chris Otiko pursuant to an employment agreement, dated January 1, 2017. Dr. Chris will serve as the Company's President for a period of three years, and agree to return 20,000,000 shares of preferred stock to the treasury for cancellation if he resigns from his position of the Company before December 31, 2019.

During the nine months ended September 30, 2017, 154,395,500 shares of common stock of the Company were issued to settle out convertible notes payable. These amount are included in the footnotes to the financial statements.

9. Any past, pending or anticipated stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization:

Stock Splits

-The Company enacted a 1 for 4 reverse stock split on July 24, 2009
-The Company enacted a 1 for 3 reverse stock split on May 25, 2010
-The Company enacted a 1 for 50 reverse stock split on May 6, 2014

Acquisition and Sale of a Subsidiary

On or about January 20, 2010 the Company acquired Wide Broad Group, Ltd., a British Virgin Island corporation ("Wide Broad"), which wholly owned Dongguan Chditn Printing Ltd., a company organized under the laws of the Peoples Republic of China. Wide Broad, through its subsidiary, operates a manufacturing plant in China that produces furniture related products. Although at one point this investment appeared promising, the investment climate in China deteriorated and as such on April 14, 2014 the Company decided to sell the Wide Broad investment to an unrelated party for a nominal amount so it can focus back on its domestic operations through the products now made available through the acquisition of ViaDerma II, Inc. as described below.

Acquisition of ViaDerma II, Inc.

On or about March 21, 2014, the Company acquired ViaDerma II, Inc. a Nevada corporation which holds the intellectual property purchased from Dr. Phillips as well as the daily operations run by our President. The Company subsequently changed its name to ViaDerma, Inc. to reflect the new direction of the Company as well as it current products. On June 4, 2014, 44,000,000 shares were issued to Dr. Chris Ayo Otiko in connection with this acquisition. The Company has since added additional intellectual property to its portfolio as described herein.

10. Any de-listing of the issuer's securities by any securities exchange or deletion from the OTC:

On March 21, 2014, the Company filed a Form 15 with the Securities and Exchange Commission to certify and notify of termination of its common stock under Section 12(g) of the Securities Exchange Act of 1934, as amended.

11. Any current, past, pending or threatened legal proceedings or administrative actions either by or against the issuer that could have a material effect on the issuer's business, financial condition, or operations and any current, past or pending trading suspensions by a securities regulator. State the names of the principal parties, the nature and current status of the matters, and the amounts involved:

On or about April 12, 2017 the Company was made aware of a lawsuit filed against the Company and several other parties in U.S. District Court for the District of South Dakota by Steven Keough, an individual. The complaint alleges, among other things, that Mr. Keough had a licensing arrangement with Dr. Howard Phillips for some of the patents related to the first-generation transdermal delivery system that were developed by Dr. Phillips. The lawsuit also alleges that Dr. Phillips should not have been able to initially license the transdermal technology to the Company. The lawsuit further alleges that, through a separate consulting agreement Dr. Chris Otiko had with Thru Pharma, LLC, an entity related to Keough, that Dr. Chris Otiko should need to assign the rights of the transdermal patent to Mr. Keough. The lawsuit seeks monetary and injunctive relief.

Based on information and belief, both agreements were breached by Thru Pharma, LLC. The Company does not believe Mr. Keough has any right to the Company's patents or technology. Furthermore, the predecessor transdermal technology, which is the subject of dispute by Mr. Keough, is not even currently used by the Company and any protections related to its provisional patents are believed to have expired. All new products being developed and sold by the Company are based on a newer transdermal technology created directly by the Company or its management team. The Company believes the lawsuit is without merit and has engaged legal counsel to vigorously defend it. The Company is also evaluating a counter-claim against Mr. Keogh.

B. Business of Issuer.

ViaDerma, Inc. is a specialty pharmaceutical company committed to bringing new products to the pharmaceutical industry through innovative research and development. The Company attempts to license and sell products in fields of medicine ranging from infectious diseases to stem-cell therapy. The Company's products are normally applied topically using a patent-pending delivery system technology originally created by Dr. Phillips and Dr. Chris Ayo Otiko. Presently, the products are used within the OTC drug market, i.e. non-prescription. However, the Company believes the delivery system can be used for the prescription medication market as well not only for topical prescription medications but also to turn certain oral medications into topically based medications.

Apart from the technology licensed from Dr. Howard Phillips, the Company is currently using a second-generation transdermal technology to manufacture and develop its products. This technology was exclusively licensed from a related party. During 2016, provisional patents were been filed on this technology. The Company received provisional patent #62433964 'AQUEOUS TOPICAL SOLUTIONS for this technology. The Company believes the newer technology has additional benefits and plans to incorporate this topical delivery system into most, if not all, of its future products

In addition to the primary plan of developing and selling new products to the market, the Company is exploring the possibility of licensing the technology to other pharmaceutical companies. As of the date of this filing, the Company has entered into two licensing and distribution agreements as follows:

On January 1, 2017, the Company entered into a licensing and distribution agreement with Biogenx, Inc. for the purpose of commercializing and distributing a topical antibiotic product to be branded VitaStem. The product will carry the Company's tetracycline-based technology. This product will be separately registered with the FDA. Pursuant to the agreement, the Company will receive 5% of the gross profit from VitaStem sales. For purposes of the agreement, gross profit is defined as total revenues less cost of production, distribution and marketing. The agreement will terminate on December 31, 2022 unless extended by both parties. Biogenx, Inc. has the right to terminate the agreement early with two month notice if it deems the arrangement to not be financially viable.

On January 1, 2017, the Company entered into a licensing and distribution agreement with Vage Nigeria, Ltd. for the purpose of commercializing and distributing a topical antibiotic product to be branded Dermafix. The product will carry the Company's tetracycline-based technology. This product will be separately registered with the FDA. Pursuant to the agreement, the Company will receive 50% of the net sales from Dermafix. For purposes of the agreement, net sales is defined as total revenues less cost of production, distribution and marketing (which includes taxes, discounts, allowances, credits for returns, rebates, import duties and other governmental charges, freight and transportation). The agreement will terminate on December 31, 2022 unless extended by both parties. Vage Nigeria, Ltd. has the right to terminate the agreement early with two month notice if it deems the arrangement to not be financially viable.

1. The issuer's primary and secondary SIC Codes;

The Primary SIC Code for the Company is
5122 – Drugs, Drug Proprietaries, and Druggist' Sundries

2. If the issuer has never conducted operations, is in the development stage, or is currently conducting operations:

The Company is, and has since inception, been conducting operations and has had revenues in each year since inception.

3. If the issuer is considered a "shell company" pursuant to Securities Act Rule 405:

The Company's management believes that the Company is not now and has never been a "shell company" as that term is defined in Rule 405 of the Securities Act.

4. The names of any parent, subsidiary, or affiliate of the issuer, and its business purpose, its method of operation, its ownership, and whether it is included in the financial statements attached to this disclosure statement.

The Company wholly owns ViaDerma II, Inc., a Nevada corporation. The financials of ViaDerma II, Inc. are included in the accompanying consolidated financial statements.

5. The effect of existing or probable governmental regulations on the business;

The Company is not aware of any government regulations that could affect its products. The active ingredients in its products have been available and approved by the FDA for several decades and the components of the delivery systems are also approved for use by the FDA.

6. An estimate of the amount spent during each of the last two fiscal years on research and development activities, and, if applicable, the extent to which the cost of such activities are borne directly by customers.

The Company estimates that, combined with Dr. Howard Philipps, $100,000 has been spent over the past three years towards research and development of its products. Dr. Phillips also used his lab facilities and staff towards the development of our delivery system.

7. Costs and effects of compliance with environmental laws (federal, state and local):

None.

8. The number of total employees and number of full-time employees.

The Company currently has 1 full-time employee. Other staff members have been hired under subcontractor arrangements.

Item IX: The nature of products or services offered.

1. Distribution methods of the products or services:

Currently, the products are sold to local medical practitioners, and patients in clinics primarily in the Los Angeles, California area. The Company's primary goal during 2017 has been to commercially manufacture the product on a larger scale and seek wholesale distribution partners that will carry and sell the product. The Company is presently using a manufacturing partner on the East Coast of the United States. During November 2017, the Company received its first finished order of Vitastem (bottle sizes range from 5ml to 15ml). The Company, along with its wholesale partners, will attempt to sell and distribute the product in several key areas during the next quarter.

Additionally, the Company has entered into two licensing and distribution agreements as described herein.

2. Status of any publicly announced new product or service:

The company is in the early development stage of a medical cannabis product (CBD) that can be absorbed through the skin with our proprietary transdermal delivery system. A provisional patent application using the combination of CBD and THC with the delivery system was filed in 2017. The use of CBD is aimed at the reduction of inflammation and for the treatment of several diseases, such as, nicotine addiction, fibromyalgia, Cohn's disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis.

In addition, the Company has filed with the Food and Drug Administration (FDA) for a new over the counter or OTC version of a "Premature Ejaculation Drug". The new "OTC Drug" received FDA registration during the second quarter of 2017 (NDC:69006-010-00) and the Company's name of the new drug will portray prolonged endurance. The Company's recent testing of the drug has proved to be successful in retarding the onset of ejaculation during sexual intercourse.

3. Competitive business conditions, the Issuer’s competitive position in the industry, and methods of competition:

There are numerous competitors in our segment of the OTC drug market that have greater market share and resources than we do. We believe our competitive edge will be our patent-pending delivery system which we believe significant increases efficacy of normal OTC medications.

4. Sources and availability of raw materials and the names of principal suppliers:

In order to be able to supply a larger volume of products we have engaged a contract manufacturer on the East Coast of the United States. We placed our first order with them for 10,000 units of Viabecline & Vitastem (5ml and 15ml) during the second quarter of 2017 and received this order during November 2017. This new manufacturer also assisted us with bottling and packaging of our product as well packaging design. Additional orders are expected to be placed during the fourth quarter of 2017.

5. Dependence on one or a few major customers:

Not applicable

6. Patents, trademarks, licenses, franchises, concessions, royalty agreements or labor contracts, including their duration; and

We currently have a non-exclusive license on U.S. patent application #20130190274, Topical Drug Delivery System with Dual Carriers. We licensed this patent from Dr. Phillips and a copy of our amended licensing agreement with Dr. Phillips is attached as Exhibit A of annual report previously filed on April 18, 2017.

On December 27, 2016, we were assigned exclusive use of a new provisional patent developed by a company controlled by our President, Dr. Chris Otiko in exchange for the cash payment of One Dollar ($1.00).

PROVISIONAL PATENT NUMBER: 62433964
ENHANCED ANTIBIOTIC AND DRUG DELIVERY FOR AQUEOUS TOPICAL APPLICATIONS
FOR HUMAN AND VETERINARY USES

Also through a company controlled by our President, Dr. Chris Otiko, we received a provisional patent (#62466209) related to the topical use of cannabis-based products.

7. The need for any government approval of principal products or services. Discuss the status of any requested government approvals.

We currently have FDA approval to sell many of our products as OTC medications. We plan to add to this list of approved products during 2017.

Item X: The nature and extent of the issuer's facilities.

Our main office is located at 6650 Reseda Blvd, Suite 101A, Reseda, CA 91335, which we use for daily operations, marketing, research and development. The office is approximately 800 square feet with annual rental expense of approximately $10,000. We believe the current office space is sufficient for the next 12 months.

Our official business mailing address is 4640 Admiralty Way, Suite 500, Marina Del Rey, California 90292.

Part D: Management Structure and Financial Information

Item XI The name of the chief executive officer, members of the board of directors, as well as control persons.

A. Officers and Directors.

President, Treasurer and Secretary

1. Full Name: Dr. Chris Ayo Otiko
2. Business Address: 4640 Admiralty Way, Suite 500, Marina Del Rey, CA 90292.
3. Employment history: For the past five years Dr. Chris Ayo Otiko has worked in the biotechnology field performing research and development. His Master of Science background in Biochemistry, along with his pioneering clinical work as a Podiatric Surgeon, allowed Dr. Chris Otiko to develop a new topical antibiotic product that won Drug Store News Best New Product award in 2012.

   Dr. Chris Otiko also personally developed and supervised R&D and Case Studies that resulted in the founding of ViaDerma, Inc., in 2014 where he now serves as Chairman of the Board and CEO. The ViaDerma products feature a ground breaking delivery system that allows for rapid mass transfer of a diverse range of pharmaceuticals through the skin and directly into the affected body part to provide immediate localized therapy.

   Prior to founding ViaDerma, Dr. Chris Otiko practiced medicine in his specialty surgical field and built / sold several medical related companies in Southern California.

   Dr. Chris Otiko received a Masters of Science Degree in Biochemistry from Oklahoma State in 1993 and a Doctorate from the California College of Podiatric Medicine, San Francisco in 1997.
4. Board memberships and other affiliations: Director
5. Compensation by the issuer: Annual salary of $30,000 in cash and one-time payment of 30,000,000 shares of Preferred Stock of the Company, 20,000,000 shares of which are subject to be cancelled if Dr. Chris Otiko resigns from his positions of the Company before December 31, 2019
6. Number and class of issuer's securities beneficially owned:

   - **40,592,854 shares of Common Stock**
   - **30,000,000 shares of Preferred Stock**

B. Legal/Disciplinary History.

1. Conviction in a criminal proceeding or named as a defendant in a criminal proceeding in the past five years: None.

2. Entry of an order, judgment, or decree, not reversed, suspended or vacated that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or bank activities: None.
3. A finding or judgment by a court (in civil action), the SEC, the Commodity Futures trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law: None.
4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended or otherwise limited such person's involvement in any type of business or securities: None.

C. Disclosure of Family Relationships.

None.

D. Disclosure of Related Party Transactions.

As of September 30, 2017 and December 31, 2016, the Company had accounts receivable balances from related parties in amount of $371,565 and $371,565, respectively. The related party sales were to either Coast to Coast Podiatry Inc. or Neurogenx Nerve Center of Newport Beach, the second office of Coast to Coast Podiatry Inc. opened in September 2016 under a different DBA. Coast to Coast Podiatry Inc. is related by virtue of the majority interest being owned by Dr. Chris Otiko, the President of the Company. In additional to the benefit of the Company receiving the sales associated with these transactions, the Company uses this platform to evaluate results and any quality control issues that could arise with the products since Dr. Chris Otiko is able to monitor both businesses.

To date, there have not been payments yet towards these amounts. However, the Company expects to begin receiving payments towards the balances during 2017.

As of September 30, 2017, the Company had due to related party in amount of $7,983.

On December 27, 2016, we were assigned an exclusive use of a new provisional patent developed by a company controlled by our President, Dr. Chris Otiko in exchange for the cash payment of One Dollar ($1.00).

PROVISIONAL PATENT NUMBER: 62433964
ENHANCED ANTIBIOTIC AND DRUG DELIVERY FOR AQUEOUS TOPICAL APPLICATIONS FOR HUMAN AND VETERINARY USES

E. Disclosure of Conflicts of Interest.

A significant portion of the Company's historic revenues are from medical offices related to our President. Additionally, The Company will also begin to market its Vitastem product through Biogenx, Inc. during the fourth quarter of 2017. Biogenx, Inc. is minority owned (25%) by the Company's President, Dr. Chris Otiko. While the Company believes these transactions are at terms that would similar to arm's length transactions, there is always a possibly a conflict of interest may arise.

Item XII: Financial information for the issuer's most recent fiscal period.

The unaudited balance sheets, statements of operations, statements of cash flows, statements of changes in stockholders' equity, and financial notes for the three and nine months ended September 30, 2017 and 2016 were simultaneously filed with this disclosure statement on November 13, 2017.

Item XIII: Similar financial information for such part of the two preceding fiscal years as the issuer or its predecessor has been in existence.

The unaudited balance sheets, statements of operations, statements of cash flows, statements of changes in stockholders' equity, and financial notes for the years ended December 31, 2016 and 2015 were previously filed on April 18, 2017.

Item XIV: Beneficial owners.

Provide a list of the name, address and shareholdings of all persons beneficially owning more than five percent (5%) of any class of the issuer's equity securities as of November 13, 2017.

Preferred Stock

Name	Address	Number Of Preferred Shares	Percentage Of Class
Dr. Chris Ayo Otiko	4640 Admiralty Way, Ste. 500, Marina Del Rey, CA 90292	30,000,000	96.77%

Common Stock

Name	Address	Number Of Common Shares	Percentage Of Class
Dr. Chris Ayo Otiko	4640 Admiralty Way, Ste. 500, Marina Del Rey, CA 90292	40,592,854	9.3%
Greentree Financial Group Inc R. Chris Cottone	7951 SW 6th Street, Suite 216 Plantation, FL 33324	9,300,000	2.0%
L&H, Inc. Vicky Huang	7951 SW 6th Street, Suite 216 Plantation, FL 33324	(1)	N/A
The Thomas Group, LLC Alan Thomas	2821 N. Ocean Blvd. #609 Ft. Lauderdale, FL	(1)	N/A

(1) Represents ownership of common shares that can be beneficially acquired through conversion into of promissory notes into common shares.

Item XV: The name, address, telephone number, and email address of each of the following outside providers that advise the issuer on matters relating to the operations, business development and disclosure:

1. Investment Banker

None

2. Promoters

None

3. Counsel

Austin Legal Group
Attorneys at Law
3990 Old Town Avenue
Suite A-112
San Diego, CA. 92110
Phone: (619) 924-9600
Email: gaustin@austinlegalgroup.com

4. Accountant or Auditor

Accountant:
L&L CPAS PA
19720 Jetton Road, 3rd Floor
Cornelius, NC 28031
Phone: (704) 897-8336
Fax: (704) 919-5089
Email: tluo@llcpas.net

5. Public Relations Consultant(s)

None

6. Investor Relations Consultant

Investment Relations:
RMJ Consulting, LLC
c/o Richard Inza
Address: 2451 SW 126th Way, Miramar, FL 33027
Phone: (954) 251-0616
Email: richardinza@gmail.com

7. Any other advisor(s) that assisted, advised, prepared or provided information with respect to this disclosure statement - the information shall include the telephone number and email

None

Item XVI: Management's discussion and analysis or plan of operation.

A. Plan of Operation: Issuer's Plan of Operation for the next twelve months.

ViaDerma, Inc. is a specialty pharmaceutical company committed to bringing new products to the pharmaceutical industry through innovative research and development. The Company attempts to license and sell products in fields of medicine ranging from infectious diseases to stem-cell therapy. The Company's products are normally applied topically using a patent-pending delivery system technology originally created by Dr. Phillips and Dr. Chris Ayo Otiko. Presently, the products are used within the OTC drug market, i.e. non-prescription. However, the Company believes the delivery system can be used for the prescription medication market as well not only for topical prescription medications but also to turn certain oral medications into topically based medications.

The Company recently engaged an Operations Manager, effective on March 1, 2017, for an initial Go-to-Market strategy. The Operation Manager will initially be responsible for overseeing product manufacturing and development. He will additionally oversee the storage, delivery and fulfillment of our products. A copy of the Independent Contractor Agreement is attached as Exhibit C of the annual report previously filed on April 18, 2017.

In addition to the primary plan of developing and selling new products to the market, the Company is exploring the possibility of licensing the technology to other pharmaceutical companies. As of the date of this filing, the Company has entered into two licensing and distribution agreements as follows:

On January 1, 2017, the Company entered into a licensing and distribution agreement with Biogenx, Inc. for the purpose of commercializing and distributing a topical antibiotic product to be branded VitaStem. The product will carry the Company's tetracycline-based technology. This product will be separately registered with the FDA. Pursuant to the agreement, the Company will receive 5% of the gross profit from VitaStem sales. For purposes of the agreement, gross profit is defined as total revenues less cost of production, distribution and marketing. The agreement will terminate on December 31, 2022 unless extended by both parties. Biogenx, Inc. has the right to terminate the agreement early with two month notice if it deems the arrangement to not be financially viable. Biogenx, Inc. is minority owned (25%) by the Company's President, Dr. Chris Otiko.

On January 1, 2017, the Company entered into a licensing and distribution agreement with Vage Nigeria, Ltd. for the purpose of commercializing and distributing a topical antibiotic product to be branded Dermafix. The product will carry the Company's tetracycline-based technology. This product will be separately registered with the FDA. Pursuant to the agreement, the Company will receive 50% of the net sales from Dermafix. For purposes of the agreement, net sales is defined as total revenues less cost of production, distribution and marketing (which includes taxes, discounts, allowances, credits for returns, rebates, import duties and other governmental charges, freight and transportation). The agreement will terminate on December 31, 2022 unless extended by both parties. Vage Nigeria, Ltd. has the right to terminate the agreement early with two month notice if it deems the arrangement to not be financially viable.

B. Management's Discussion and Analysis of Financial Condition and Results of Operations.

For the three and nine months ended September 30, 2017 and 2016 (Unaudited)

Revenues and Cost of Sales

The Company had revenues of $7,002 and $26,802 for the three and nine months ended September 30, 2017, respectively, as compared with $83,500 and $209,573 for the same periods in 2016. The decrease was primarily due to the Company's strategy to shift selling focus to wholesale distributors instead of mostly local physicians. The Company believes this strategy will be a key component to achieve significant revenue growth. Thus far, the Company has entered into agreements with two distributors during the first nine months of the year and plans to enter into additional agreements during the fourth quarter. Although new orders from these distributors have not been placed to date, the Company believes initial volume indications are very encouraging. The Company experienced a delay in receiving its first large-scale order of its products from its new manufacturer as and such some initial new orders needed to be pushed back until the product arrives. The Company received this order in November 2017 and is now ready and available to fulfill product orders.

The Company had accounts receivable from related party in amount of $371,565 as of September 30, 2017 due to the related party sales in 2016 and 2015. The related party sales were to either Coast to Coast Podiatry Inc. or Neurogenx Nerve Center of Newport Beach, the second office of Coast to Coast Podiatry Inc. opened in September 2016 under a different DBA. Coast to Coast Podiatry Inc. is related by virtue of the majority interest being owned by Dr. Chris Otiko, the President of the Company. In additional to the benefit of the Company getting the sales associated with these transactions, the Company uses this platform to evaluate results and any quality control issues that could arise with the products since Dr. Chris Otiko is able to monitor both businesses. The Neurogenx Nerve Center DBA was recently closed but the primary entity, Coast to Coast Podiatry, Inc., is still obligated to make payments on the receivable balance.

To date, there have not been payments yet towards these amounts. However, the Company expects to begin receiving payments towards the balances during 2018.

Cost of sales were $1,400 and $5,546 for the three and nine months ended September 30, 2017, respectively, compared with $5,984 and $8,298 for the same periods in 2016, respectively. Cost of sales were primarily attributable to the cost of manufacturing and bottling our products. We expect sales to grow in 2017 and moving forward as we build awareness for our products and attempt to sell to larger pharmaceutical product retailers through distributors. We also expect margins to improve if we are successful in selling larger volumes of our products.

Operating Expenses

We had operating expenses of $137,666 and $509,915 for the three and nine months ended September 30, 2017, respectively. This compares with $58,756 and $173,336 for the same periods in 2016, respectively. Operating expenses were higher during 2017 primarily due to increases in stock based compensation, professional fees and officer's compensation which were $142,050, $98,000 and $180,000 for the 2017 nine-month period, respectively.

The stock based compensation was attributable to 4,500,000 shares of common stock issued for services pursuant to a product marketing contract signed with BK Consulting, LLC. However, the Company and the vendor have had a dispute as to the scope and deliverables of the contract and the contract was cancelled during the third quarter of 2017 prior to any services being rendered. The Company is expecting the shares to be returned and eventually retired back to the Company's treasury. Upon receipt of these shares, the Company will process a corresponding credit to the same expense account.

The professional fees of $20,000 and $98,000 for the three and nine months ended September 30, 2017 were primarily due to public company compliance costs as well as litigation costs connected to the Steven Keough intellectual property lawsuit as described herein.

The officer compensation of $60,000 is due to the cash and non-cash portions of payments to our President, Dr. Chris Otiko.

On January 1, 2017, the Company entered into an employment agreement with Dr. Chris A. Otiko, the Company's President, pursuant to which the Company agreed to compensate Dr. Chris Otiko for his contribution and work as the Company's President for a period of three years in amount of $30,000 per year in cash, plus one-time payment of 30,000,000 shares of Preferred Stock of Company, 20,000,000 shares of which are subject to be cancelled if Dr. Chris Otiko resigns from his position of the Company before December 31, 2019. This employment agreement may be renewed upon mutual written consent.

Based on the price of $.021 per share for the Preferred Stock, which was determined by the market price of common stock at $.0021 per share on the grant date multiplied by the conversion ratio of 1:10, the fair value of the issuance of Preferred Stock was $630,000. Accordingly, the Company booked the stock based compensation pro rata within the relative service period. For the three months ended September 30, 2017, the Company recognized $52,500 to the consolidated statements of operations. The unrecognized compensation was recorded as deferred compensation amounting to $472,500 as of September 30, 2017.

We expect our operating expenses will significantly increase in 2018 as we attempt to build our product line and market our products. However, both operating costs and expected revenue generation are difficult to predict. There can be no assurance that revenues will be sufficient to cover future operating costs, and it may be necessary to continuously raise additional capital to sustain operations.

Product Marketing Contracts

During the second quarter of 2017, the Company engaged four entities to assist in marketing of the Company's products, primarily in South America. Based on certain performance measures, these entities would have received up to 65,000,000 shares of common stock. Immediately after the agreements were signed there arose a dispute as to the performance measures and the Company did not feel that the written agreements actually portrayed the desires and goals of the Company. Therefore, in the third quarter 2017 the Company sent a notice of cancellation to the parties. As described above, only 4,500,000 of the shares were actually issued pursuant to the agreements. The Company has already received one mutual release from one of the entities representing a maximum of 11,500,000 shares and has reached an agreement in principle to get a release from the other the parties in exchange for a small cash payment. Upon satisfaction of the settlement, the Company expects the 4,500,000 common shares to be returned to the treasury for cancellation.

Income/Losses

We had net losses of $180,673 and $806,657 for the three and nine months ended September 30, 2017 compared with net losses of $30,796 and $217,318 during the same periods in 2016, respectively. The net losses during 2017 increased primarily due to the increase in operating expenses described and also an increase in derivative expenses in connection with the Company's convertible notes payable which were $509,915 and $140,089, respectively. We are attempting to negotiate payoffs on most of our promissory notes which, if successful, would remove most of our future interest charges. In addition, we also expect to increase sales and marketing costs during 2018.

Impact of Inflation

We believe that inflation has had a negligible effect on operations since inception. We believe that we can offset inflationary increases in the cost of operations by increasing sales and improving operating efficiencies.

Liquidity and Capital Resources

During the nine months September 30, 2017, net cash flows used in operating activities was $129,573, compared to net cash flows of $1,228 provided by operation in the first nine months of 2016. Negative cash flow in the first nine months of 2017 was due primarily to our net loss of $806,657, partially offset by the non-cash expenses including stock based compensation of $276,750, note issue for services of $69,000, derivative related expense of $140,089, amortization of debt discount of $109,881 and an increase in accrued interest payable by $68,028. Net cash flows provided by operating activities in the first nine months of 2016 was due primarily to the increase in accrued interest payable by $92,111, plus the non-cash expenses including derivative liabilities expense of $37,052 and amortization of debt discount of $122,769, partially offset by the net loss of $217,318.

There were no cash flows from investing activities during the nine months ended September 30, 2017 and 2016.

During the nine months ended September 30, 2017 and 2016, net cash flows provided by financing activities were $129,600 and $5,964, respectively, due to the $79,600 in proceeds from a line of credit and $50,000 in proceeds from two notes payable as discussed in the notes to the financial statements. On July 12, 2016, the Company issued an unrelated third party a 15% promissory note (the "Line of Credit") with 20% prepayment penalty and 20% default charge, pursuant to which the note holder agreed to invest total amount up to $200,000 into the Company for working capital.

We had cash on hand of $9,870 and a working capital deficit of $577,602 as of September 30, 2017. On the short-term basis, we will be required to raise a significant amount of additional funds over the next 12 months to sustain operations. On the long-term basis, we will potentially need to raise capital to grow and develop our business. We currently have additional funds available to us of approximately $100,000 under our July 2016 credit line. Additionally, we plan to initiate an equity offering under Regulation A during the fourth quarter to attempt to raise additional equity capital. If successful, proceeds from this offering will be used to pay down debts and fund our working capital.

In preparation of our common stock offering, on or about August 3, 2017 we amended our Articles of Incorporation to increase our authorized shares of common stock to 750,000,000. Authorized preferred shares amount remain unchanged.

C. Off-Balance Sheet Arrangements: None

Part E: Issuance History

Item XVII: List of securities offerings and shares issued for services in the past two years.

List below any events, in chronological order, that resulted in changes in total shares outstanding by the issuer (1) within the two-year period ending on the last day of the issuer's most recent fiscal year and (2) since the last day of the issuer's most recent fiscal year.

Between January 1, 2015 and December 31, 2015:

Non-Restricted Restricted Common Shares Issuance:
Number of shares issued: 33,430,671
Legend: N/A

Between January 1, 2016 and December 31, 2016:

Non-Restricted Common Shares Issuance:
Number of shares issued: 151,276,316
Legend: N/A

Between January 1, 2017 and present:

Non-Restricted Common Shares Issuance:
Number of shares issued: 154,395,500
Legend: N/A

Restricted Preferred Shares Issued:
Number of shares issued: 4,500,000
Legend: Rule 144

Part F: Exhibits

Item XVIII: Material Contracts:

A copy of our licensing agreement with Dr. Phillips was previously filed as Exhibit C on June 10, 2014.

A copy of our License and Distribution Agreement, dated September 30, 2016, and amended licensing agreement with Dr. Phillips is attached as Exhibit A of annual report previously filed on April 18, 2017.

A copy of Employment Agreement with Dr. Chris Otiko, our President, effective on January 1, 2017 is attached as Exhibit B of annual report previously filed on April 18, 2017.

A copy of Independent Contractor Agreement with Ivan Klarich, effective on March 1, 2017 is attached as Exhibit C of annual report previously filed on April 18, 2017.

Item XIX: Articles of Incorporation and Bylaws.

Articles of Incorporation and all the amendments and bylaws were previously filed as Exhibit D on June 10, 2014

The amendments to our Articles of Incorporation filed on August 3, 2017 related to the increase in our authorized shares is attached as Exhibit A

Item XX: Purchases of Equity Securities by the Issuer and Affiliated Purchasers.

None.

Item XXI Issuer's Certifications.

I, Dr. Chris Ayo Otiko certify that:

1. I have reviewed this Information and Disclosure Statement of ViaDerma, Inc.

2. Based on my knowledge, this Information and Disclosure Statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Information and Disclosure Statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this Information and Disclosure Statement.

Date: November 13, 2017

/s/ Dr. Chris Ayo Otiko
Dr. Chris Ayo Otiko
President